Helix BioPharma (TSE:HBP) Stock Crosses Below 50-Day Moving Average – Here’s Why

Helix BioPharma Corp. (TSE:HBP) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$1.64 and traded as low as C$1.58. Helix BioPharma shares last traded at C$1.63, with a volume of 5,473 shares.

Helix BioPharma Price Performance

The business’s 50-day moving average price is C$1.65 and its 200 day moving average price is C$1.70. The stock has a market capitalization of C$110.75 million, a PE ratio of -36.25 and a beta of 0.72. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.03 and a current ratio of 0.45.

Helix BioPharma (TSE:HBP) last issued its quarterly earnings data on Friday, June 12th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. Research analysts forecast that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.